Home
News
Create
Screeners
Insights
Amanta Healthcare
95.
73
-2.65
(-2.69%)
Market Cap
₹371.71 Cr
PE Ratio
25.04
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-2.69%
1M
-11.82%
6M
-31.56%
1Y
-32.47%
5Y
-32.47%
View Company Insights
Latest news about Amanta Healthcare
Amanta Healthcare Promoter Increases Stake Through Open Market Purchase
Feb 27, 2026
Amanta Healthcare Limited disclosed that promoter Bhavesh Girishbhai Patel acquired 48,151 equity shares worth ₹50.20 lakh through open market purchases on February 26-27, 2026. The transaction increased his shareholding from 62,49,593 shares (16.10%) to 62,97,744 shares (16.22%). The disclosure was made under SEBI Insider Trading Regulations with shares purchased through NSE market transactions.
Amanta Healthcare Hosts Maiden Earnings Call, Outlines ₹150 Crore Revenue Expansion Plan
Feb 16, 2026
Amanta Healthcare Limited Announces Changes in Senior Management Personnel
Feb 10, 2026
Amanta Healthcare Opens Special Window for Transfer and Dematerialisation of Physical Securities
Feb 02, 2026
Amanta Healthcare Corrects Solar Power Plant Capacity to 10.8 MWp in Revised Agreement
Jan 02, 2026
More news about Amanta Healthcare
14
Nov 25
Amanta Healthcare Allocates Rs 3,030 Crore from IPO Proceeds for Expansion
Amanta Healthcare Limited has used Rs 3,030.02 lakhs from its IPO proceeds for the quarter ending September 30, 2025. The funds were primarily used for capital expenditure at its Gujarat facility, including manufacturing equipment and civil construction. The company still has Rs 9,569.98 lakhs available for further planned expansions. Amanta plans to commence a SteriPort Manufacturing Line in January 2026 and an SVP Manufacturing Line in January 2027, both located in Hariyala, Kheda, Gujarat. For Q2 FY2026, the company reported a total income from operations of Rs 7,095.80 lakhs and a net profit after tax of Rs 120.76 lakhs.
12
Nov 25
Amanta Healthcare Reports Fund Utilization Deviation and Q2 FY2026 Financial Results
Amanta Healthcare Limited disclosed a deviation in IPO fund utilization due to GST payment changes, adjusting issue expenses and reducing general corporate purpose expenses. The company's Q2 FY2026 results show revenue growth to Rs. 7,088.73 lakhs, but a decrease in net profit to Rs. 120.75 lakhs compared to Q2 FY2025. Half-year performance improved with revenue at Rs. 13,619.44 lakhs and net profit at Rs. 471.47 lakhs. Balance sheet highlights include increased total assets of Rs. 48,831.55 lakhs and improved cash position of Rs. 9,196.41 lakhs as of September 30, 2025.
12
Nov 25
Amanta Healthcare Reports Q2 Profit, Completes IPO Listing
Amanta Healthcare Limited reported Q2 FY2026 results with total income of Rs. 7,095.80 lakhs and net profit of Rs. 207.80 lakhs. For H1 FY2026, total income was Rs. 13,850.45 lakhs with net profit of Rs. 185.50 lakhs. The company completed its IPO, issuing 10 million shares at Rs. 126 each, raising Rs. 12,600 lakhs. Listing occurred on September 9, 2025, on BSE and NSE. IPO proceeds are allocated for new manufacturing lines and corporate purposes, with Rs. 3,030.02 lakhs utilized so far. PriceWaterhouseCoopers provided an unmodified review opinion on the financial results.
Amanta Healthcare
95.
73
-
2.
65
(-
2.
69
%)
1 Year Returns:
-32.47%
Industry Peers
Sun Pharmaceutical
1,801.60
(-
1.
30
%)
Divis Laboratories
6,071.00
(-
3.
36
%)
Torrent Pharmaceuticals
4,390.00
(-
1.
26
%)
Dr Reddys Laboratories
1,292.30
(-
2.
02
%)
Cipla
1,314.70
(-
0.
72
%)
Lupin
2,314.90
(-
1.
80
%)
Zydus Life Science
905.90
(-
1.
20
%)
Mankind Pharma
2,138.90
(-
3.
13
%)
Aurobindo Pharma
1,296.50
(-
1.
17
%)
Alkem Laboratories
5,355.50
(-
1.
63
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO